Drugs / GP-100 Peptide Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00861406 | Mar 2009 → Feb 2017 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP-100 Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00861406 ↗ |
| Modality | Vaccine | “gp100 vaccine has been shown to stimulate the immune system” NCT00861406 ↗ |
| Route | Subcutaneous | “Injection under skin once every 3 weeks” NCT00861406 ↗ |